Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (58,327)	$ (21,267)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	579	59
Net (accretion) and amortization of investments in marketable securities	(3,771)
Change in fair value of preferred stock tranche right liability	7,390	1,030
Non-cash lease expense	477	52
Stock-based compensation expense	7,027	2,527
Series A and B preferred stock issuance costs allocated to tranche right liabilities		67
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,842)	(1,315)
Other assets	51	(125)
Accounts payable	(994)	131
Accrued expenses and other current liabilities	(477)	2,003
Operating lease liabilities	(495)	14
Net cash used in operating activities	(50,382)	(16,824)
Cash flows from investing activities
Purchases of short-term investments	(292,973)
Maturities of short-term investments	93,081
Purchases of property and equipment	(2,179)	(199)
Net cash used in investing activities	(202,071)	(199)
Cash flows from financing activities
Proceeds from initial public offering and concurrent private placement, net of underwriter discounts and commissions and deferred offering costs	157,705
Proceeds from issuance restricted common stock		54
Repurchase of unvested restricted common stock		(4)
Net cash provided by financing activities	221,618	145,276
Net (decrease) increase in cash, cash equivalents, and restricted cash	(30,835)	128,253
Cash, cash equivalents, and restricted cash at beginning of period	70,254	31,159
Cash, cash equivalents, and restricted cash at end of period	39,419	159,412
Supplemental disclosure for noncash investing and financing activities:
Deferred offering costs included in accounts payable and accrued expenses at period end		(6)
Purchases of property and equipment included in accounts payable and accrued expenses at period end	17	208
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	39,314	159,412
Restricted cash	105
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	39,419	159,412
Series A Convertible Preferred Stock
Cash flows from financing activities
Proceeds from issuance of convertible preferred stock, net of issuance costs paid		59,920
Supplemental disclosure for noncash investing and financing activities:
Conversion of convertible preferred stock into common stock upon closing of initial public offering	89,487
Series B Convertible Preferred Stock
Cash flows from financing activities
Proceeds from issuance of convertible preferred stock, net of issuance costs paid	63,913	85,306
Supplemental disclosure for noncash investing and financing activities:
Conversion of convertible preferred stock into common stock upon closing of initial public offering	145,252
Series A Preferred Stock
Supplemental disclosure for noncash investing and financing activities:
Settlement of preferred stock tranche right liability		11,465
Series B Preferred Stock
Supplemental disclosure for noncash investing and financing activities:
Settlement of preferred stock tranche right liability	$ 11,590	$ 581